OncoMed 8-K Shows On Oct. 15, Celgene Notified Co. Of Decision Not To Exercise Option To License Rosmantuzumab; OncoMed Will Retain Worldwide Rights To Rosmantuzumab Upon Termination Of Collaboration Deal With Celgene